Pharmacist-Inpatient

M42 launches new healthcare platform 'Beyond Bounds' * Follow author on M42 has launched Beyond Bounds, a new global thought leadership platform that brings together insights from leading scientists, researchers, policymakers, business leaders, and innovators on the trends and breakthroughs shaping the future of healthcare worldwide. Beyond Bounds supports M42's mission to challenge traditional healthcare models by bringing together leading minds and influential players from across the industry to examine emerging developments and shape the future of healthcare. The platform aims to advance a model centered on prediction, prevention and precision, while fostering new ideas and exploring the possibilities created when expertise and experience are shared across disciplines, institutions and borders. You may like. The new M42's platform launches at a critical juncture for the healthcare sector, as advances in genomics, artificial intelligence, precision medicine and diagnostics expand the ability of health systems to predict, prevent and treat disease. At the same time, progress remains uneven across regions. More than 80 percent of genomic clinical studies are concentrated in high-income countries, while persistent health inequalities, gaps in innovation and uneven access to advanced therapies continue to pose significant challenges to healthcare systems worldwide. Against this backdrop, Beyond Bounds aims to challenge established approaches, encourage new thinking and foster dialogue across borders and disciplines. "The questions shaping the future of health are becoming bigger, more complex and more interconnected. Answering them requires us to collaborate more and search for answers by looking beyond our own organizations, disciplines and health systems. At the same time, we must continue to push boundaries, challenge the status quo and explore new possibilities to find the solutions for global health progress. That is the thinking behind Beyond Bounds. This platform brings together leading voices, the brightest minds and biggest thinkers to challenge assumptions, share learnings and push through ideas for meaningful impact." M42's new platform explores the forces shaping the future of healthcare. Content is organized across five editorial pillars: * Beyond AI - Examining the future of AI in health; * Beyond Borders - Addressing gaps across health systems and populations; * Beyond Treatment - Focused on prevention and longevity; * Beyond Science - Exploring emerging discoveries and their potential to reshape health and medicine; * Beyond Genomics - Covering genetics and genomics. Furthermore, the platform features original articles, expert commentary, video, and podcasts from industry experts from around the world. Its first collection tackles questions at the forefront of healthcare today, with Masamitsu Harata, Founder, Chairman, President and CEO of Human Life CORD Japan, exploring the potential of umbilical cord-derived cells in regenerative medicine; Dr. David Bearss, CEO and Co-Founder of Halia Therapeutics, examining how a deeper understanding of genetic resilience could shape the next generation of therapeutics; and Professor Simon Fishel, CEO of ProFaM and a pioneer in reproductive medicine, exploring how advances in ovarian tissue preservation could change the way we think about fertility, menopause and healthy ageing.

M42 advances Central Asia ambitions as Diaverum enters Kyrgyzstan, marks 10 years in Kazakhstan. 22 Sep 2026 15:06 ABU DHABI (WAM) M42, a global health leader powered by artificial intelligence (AI), technology and genomics, today announced that its world-leading renal care business, Diaverum, is opening its first clinic in Kyrgyzstan, marking an expansion for M42 in the Central Asia region. This expansion comes as Diaverum celebrates its 10-year anniversary in Kazakhstan, the largest country in the region, and follows M42's strategic partnership with Uzbekistan's Ministry of Health to collaborate and explore opportunities for strategic partnerships on the Uzbek Genome Programme. Combined, M42's growing presence in the region reflects its ambition to support healthcare systems by combining specialised care delivery with capabilities in genomics, AI, and digital health. Located in Bishkek, the new Diaverum clinic in Kyrgyzstan creates a platform for future growth and collaboration with the local healthcare system. Nearly half a million adults in Kyrgyzstan are estimated to be living with chronic kidney disease, with recent research indicating a prevalence of 10.8% among the country's adult population, underlining the need for accessible, high-quality renal care. The clinic's official inauguration was hosted by Amantur Ryskulov, General Manager, Diaverum Southeast Asia and Central Asia, and attended by Ziyad Kabli, Chief Operations Officer, M42 Middle East and Asia, together with other members of the regional leadership team at M42; Mohamed Salmeen, Head of Support Services, Consular Affairs and Nationals Services Section at the UAE Embassy in Bishkek; Nurlan Mamyrov, Honorary Consul of Sweden to the Kyrgyz Republic; the management of the Ministry of Health of the Kyrgyz Republic and the National Investment agency under the President of the Kyrgyz Republic, as well as senior representatives from public health authorities and other government bodies. The clinic will begin operations with 15 dialysis stations running three shifts from Monday to Saturday, with the potential to expand capacity to 20 stations over time. It will introduce Diaverum's established AI-enabled, patient-centred Care Delivery Model, combining international clinical standards, strong clinical governance and local expertise to support safe, consistent and high-quality care. While initially focusing on delivering high-quality dialysis services, the Bishkek clinic aims to work with local healthcare stakeholders to support a broader approach to kidney health, including prevention, early intervention, peritoneal dialysis, home care and the coordinated management of related health conditions. Group Chief Executive Officer of M42, Dimitris Moulavasilis, commented on the opening, "At M42, we are building a global health intelligence platform that brings together clinical expertise, technology, data and genomics to address complex health challenges. Our growth in Central Asia demonstrates how our model can support different healthcare priorities from specialised renal care in Kazakhstan and Kyrgyzstan to advancing prevention-first care in Uzbekistan. Through strong local partnerships, we aim to contribute to more connected, sustainable and future-ready healthcare systems across the region that serve people with their healthcare needs." Chief Operating Officer, Middle East & Asia at M42, Ziyad Kabli, said, "Central Asia is an important growth region for M42, and our approach is grounded in long-term collaboration aligned with local healthcare priorities. Kazakhstan demonstrates what can be achieved through sustained commitment, while our entry into Kyrgyzstan expands access to high-quality renal care. Alongside our partnership in Uzbekistan, these developments demonstrate M42's commitment to more integrated, preventive and data-enabled healthcare across the region." The expansion into Kyrgyzstan builds on Diaverum's decade-long contribution in Kazakhstan. Since entering the country with nine clinics, Diaverum has grown into Kazakhstan's largest private dialysis provider, operating a nationwide network of more than 55 clinics, serving thousands of patients and employing over 1,000 healthcare professionals and support staff. As M42 continues to expand globally, its engagement across Kazakhstan, Kyrgyzstan, and Uzbekistan demonstrates its diverse capabilities to support the priorities of different healthcare systems.

M42 to adopt Oracle Health Data Intelligence to advance AI-powered precision healthcare in UAE. WAM 15 Sep 2026, 15:33 GMT+ ABU DHABI, 15th September, 2026 (WAM) - M42, a global health leader powered by AI, technology and genomics, today announced plans to adopt Oracle Health Data Intelligence to help unify clinical, genomic and real-world data across its network, advancing chronic disease management, population health programmes and precision care delivery. The collaboration marks another milestone in M42's ongoing efforts to strengthen the UAE's position as a global hub for healthcare innovation and AI-enabled healthcare transformation. Through the integration of Oracle Health Data Intelligence with Oracle Health Foundation EHR, M42 aims to create a secure, scalable and intelligent healthcare ecosystem that enables clinicians and researchers to generate faster insights, enhance care coordination and improve patient experiences. M42's broader vision is to unlock the full potential of Oracle Health solutions across its network to deliver a more connected clinician experience and seamless patient journeys. By centralising diverse healthcare data sources into a unified environment, the platform will help equip clinicians with actionable insights at the point of care while enabling more informed and personalised healthcare delivery. As healthcare systems increasingly rely on complex and rapidly expanding datasets, the collaboration will further strengthen M42's ability to harness data intelligence to optimise healthcare delivery, support healthier populations and accelerate innovation in AI-driven care models and medical research. Underpinned by comprehensive data, digital and AI governance principles, it will help ensure healthcare data is managed securely and responsibly, enabling trusted innovation while supporting regulatory compliance. The announcement builds on the strategic collaboration launched last year between M42 and Oracle Health to support the creation of unified longitudinal patient records accessible across the UAE healthcare ecosystem. As part of that initiative, the organisations successfully integrated data from the Emirati Genome Programme into the electronic health record system to make pharmacogenomic information available to clinicians to support more personalised, data-driven treatment pathways. Dr. Ali Anees, Chief Operating Officer UAE and Bahrain at M42, said, "M42 has a long-standing strategic relationship with Oracle Health, and the adoption of Oracle Health Data Intelligence represents an important step forward in our mission to redefine the future of healthcare through AI and data." He added, "By bringing together clinical, genomic and real-world data into one secure and intelligent environment, we are enabling faster discovery, more predictive insights, and more personalised care for patients. This initiative strengthens our ability to translate data into meaningful health outcomes while advancing the UAE's vision for AI-powered healthcare innovation." The initiative will also support M42's vision to create a comprehensive longitudinal patient record, equipping clinicians across its network with a more complete understanding of patient health histories to support informed clinical decision-making and seamless care coordination. From a population health perspective, the unified platform will enable advanced analytics and AI-driven exploration across large datasets, helping researchers identify disease patterns, correlations and risk factors more efficiently. Built-in AI capabilities will support earlier detection of emerging health trends and treatment opportunities that may otherwise be difficult to identify through traditional analysis methods. Seema Verma, Executive Vice President and General Manager, Oracle Health and Life Sciences, said, "Oracle Health's collaboration with M42 reflects our shared commitment to harnessing the full value of healthcare data, genomics, and AI to transform patient care and accelerate innovation." She added, "M42 continues to demonstrate global leadership in AI-enabled healthcare innovation, and this collaboration highlights how advanced data platforms can help improve research, care delivery and population health outcomes at scale." M42 plans to initially deploy Oracle Health Data Intelligence within its diabetes programmes, enabling proactive patient engagement and care optimisation to help improve long-term health outcomes for individuals living with chronic conditions.